Ginkgo Bioworks Holdings DNA

Ginkgo Bioworks Holdings Inc. is a biotech company that focuses on genetic engineering. Based in Boston, Massachusetts, the company focuses on developing synthetic biology products for use in a range of industries. Founded in 2009, Ginkgo was birthed by a group of MIT students including CEO Jason Kelly, who saw the potential future value in biological technologies.

The fundamental message the company communicates is that “biology is the most advanced manufacturing technology on the planet” and builds on this to produce a range of biosynthetic solutions. Ginkgo products and technologies are used in food, material production and therapeutics. Their key areas of focus include Enzyme Discovery, Strain Improvement, Biosecurity and Mammalian Cell Engineering.

Ginkgo went public in September 2021, through a merger with Soaring Eagle Acquisition Corp., a special purpose acquisition company (SPAC). The IPO raised approximately $1.6 billion at the time, making it one of the biggest biotech IPOs to date. On floating, the company had an approximate value of $15 billion. Ginkgo trades on the NYSE with the ticker DNA, which was formerly used by Genentech until their acquisition by Roche.

Stay up to date on the latest share price trends of Ginkgo Bioworks Holdings by adding it to your eToro virtual portfolio.